111 patents
Page 2 of 6
Utility
Methods of Treating Pregnancy-associated Atypical Hemolytic Uremic Syndrome Using an ANTI-C5 Antibody
9 Feb 23
Provided are methods for clinical treatment of pregnancy-associated atypical haemolytic uraemic syndrome (p-aHUS), including postpartum aHUS, using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
Andrew E. Denker
Filed: 18 Dec 20
Utility
High Concentration ANTI-C5 Antibody Formulations
5 Jan 23
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Leena Philominathan, Bruce Mason
Filed: 4 Nov 20
Utility
Unit Dose Formulation of Antidotes for Factor Xa Inhibitors and Methods of Using the Same
5 Jan 23
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa.
Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
Filed: 5 Jan 22
Utility
Method and System for Improved Management of Genetic Diseases
15 Dec 22
The present disclosure provides a method for genetic analysis for disease diagnoses, as well as a system for implementing such analysis.
Stephen Kingsmore, Narayanan Veeraraghavan, Sebastien Lefebvre
Filed: 10 Jun 22
Utility
Methods of Reducing Neurological Damage In Wilson Disease Patients
8 Dec 22
This disclosure generally relates to methods of treating copper-induced neurological damage observed in copper metabolism-associated diseases or disorders.
Thomas Plitz, Sabine Borchard, Hans Zischka
Filed: 20 Nov 20
Utility
Methods for Treating Lysosomal Acid Lipase Deficiency In Patients
17 Nov 22
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency.
Anthony QUINN
Filed: 30 Jun 22
Utility
Complement Inhibitors for Treating Drug-induced Complement-mediated Response
10 Nov 22
Disclosed herein are methods and compositions for reducing or eliminating a complement-mediated response in a patient receiving treatment for a disease or disorder wherein one or more therapeutic agents is administered to the patient along with one or more complement inhibitors.
Yi Wang, Susan Liu-Chen
Filed: 1 Oct 20
Utility
Lyophilized Formulations for Factor Xa Antidote
10 Nov 22
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes.
Phuong M. Nguyen
Filed: 18 Mar 22
Utility
Glycoprotein Manufacturing Process
3 Nov 22
The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) inoculating Chinese Hamster Ovary (CHO) cells expressing recombinant alkaline phosphatase in culture medium; (ii) culturing the CHO cells in the culture medium at a temperature of about 37° C.; (iii) adding a combination of nutrient supplements to the cell culture of (ii) at least one day after inoculation, the combination comprising (a) a first animal-derived component-free (ADCF) nutrient supplement comprising one or more amino acids, vitamins, salts, trace elements, poloxamer and glucose, wherein the first ADCF nutrient supplement does not comprise hypoxanthine, thymidine, insulin, L-glutamine, growth factors, peptides, proteins, hydrolysates, phenol red and 2-mercaptoethanol; and (b) a second ADCF nutrient supplement comprising one or more amino acids, wherein the second ADCF nutrient supplement lacks hypoxanthine, thymidine, insulin, L-glutamine, growth factors, peptides, proteins, hydrolysates, phenol red, 2-mercaptoethanol and poloxamer; (iv) decreasing the temperature of the cell culture of (iii) to about 30° C. about 80 hours to 120 hours after the inoculation; and (v) isolating the recombinant alkaline phosphatase from the cell culture of (iv) by at least one chromatography step.
Krishanu MATHUR, Siguang SUI
Filed: 5 Mar 18
Utility
Methods of Measuring Copper Concentration In Biological Samples
20 Oct 22
This disclosure relates to methods of measuring copper concentrations in biological samples.
Mark Ma, Tao Liang, Ryan Pelto
Filed: 11 Sep 20
Utility
Virus Filtration
20 Oct 22
Provided herein are methods of performing viral filtration on a fluid including a recombinant antibody, and the use of these methods in methods of manufacturing or producing the recombinant antibody.
Bianca OLSON, Saravanamoorthy RAJENDRAN, Ryan TEDSTONE
Filed: 20 Apr 22
Utility
Recombinant Glycosylated Eculizumab and Eculizumab Variants
13 Oct 22
The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns.
Bruce Andrien, Jeffrey William Hunter, Hunter F. Malanson
Filed: 12 Apr 22
Utility
Use of Anti-fcrn Antibodies In the Treatment of Pemphighus and Pemphigoid Diseases
22 Sep 22
The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor.
Laurence J. Blumberg, Richard S. Blumberg, John Humphries
Filed: 18 May 20
Utility
Alkaline Phosphatase Polypeptides and Methods of Use Thereof
25 Aug 22
Featured are pharmaceutical compositions that include a soluble alkaline phosphatase for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof.
Walter C. VOEGTLI, Yuhong WU, Jonathan MONTELEONE, Tatyana MEZHEBOVSKY, Eric FALCONE, Yang GUO
Filed: 10 Feb 22
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis with Eculizumab
18 Aug 22
The disclosure provides methods of treating refractory myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Jing Jing Wang, Warren Wasiewski, Fanny O'Brien, Kenji Fujita
Filed: 4 Aug 20
Utility
Compositions and Methods for Preparing Factor Xa and Derivatives
11 Aug 22
The present disclosure relates to protein sequences which can be used to generate factor Xa proteins and derivatives thereof.
Genmin Lu
Filed: 5 Aug 20
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Atypical Hemolytic Uremic Syndrome (Ahus)
28 Jul 22
Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
Lori Payton, Christian Mix, Rajendra Pradhan, Andrew Damokosh, Eugene Scott Swenson, Xiang Gao
Filed: 24 Jan 20
Utility
Methods for Treating Lymphoma
28 Jul 22
Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided.
Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
Filed: 31 Jan 22
Utility
Methods of Treating Vitiligo Using an ANTI-C5 Antibody
21 Jul 22
Provided are methods for clinical treatment of vitiligo using an anti-CS antibody or antigen binding fragment thereof.
Richard Alexander Wells
Filed: 20 May 20
Utility
Monovalent Anti-properdin Antibodies and Antibody Fragments
26 May 22
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin.
Douglas L. SHERIDAN, Paul P. TAMBURINI, Taneisha Ann-Tanara MACK, Walter C. VOEGTLI
Filed: 9 Nov 21